1 / 7

EpiCast Dyslipidemia,Epidemiology Market Size 2023

Research Beam adds a report titled “EpiCast Report,Dyslipidemia Epidemiology Forecast 2023” that provides detailed information of the Dyslipidemia Epidemiology.The report is an excellent piece of study for investors who are looking towards the market. Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease, and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial. GlobalData epidemiologists forecast that the total prevalent cases of dyslipidemia in the 8MM will increase from 572,418,492 total prevalent cases in 2013, to 685,905,635 total prevalent cases in 2023, at an Annual Growth Rate (AGR) of 1.99%. All markets will see an increase in the total prevalent cases of dyslipidemia at varying AGRs, except for Germany, which will see a decrease. The 8MM had an estimated 3,339,447 total prevalent cases of FH in 2013, and the number of total prevalent cases of FH is expected to increase to 4,365,831 by 2023, at an AGR of 3.07%. All markets will see an increase in the total prevalent cases of FH at varying AGRs, except for Japan, which will see a decrease. Additionally, GlobalData epidemiologists forecast that the total prevalent cases of increased LDLc in the 8MM will increase from 345,008,543 total prevalent cases in 2013 to 411,737,455 total prevalent cases in 2023, at an AGR of 1.93%. All markets will see an increase in the total prevalent cases of increased LDLc at varying AGRs, except for Germany, which will see a decrease. The 8MM had an estimated 10,777,756 total prevalent cases of very high TG (=500mg/dL) in 2013, and the number of total prevalent cases of very high TG is expected to increase to 12,746,492 by 2023, at an AGR of 1.83%. All markets will see an increase in the total prevalent cases of very high TG at varying AGRs, except for Germany and Japan, which will see a decrease. GlobalData epidemiologists used comprehens

Florence_2012
Télécharger la présentation

EpiCast Dyslipidemia,Epidemiology Market Size 2023

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EpiCast Report: Dyslipidemia Epidemiology Forecast to 2023 (Type, Mode of action, Crop Type and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020 • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@researchbeam.com Published on : Oct 2014

  2. Report Overview Research Beam adds a report titled “EpiCastReport,Dyslipidemia Epidemiology Forecast 2023” that provides detailed information of the Dyslipidemia Epidemiology.The report is an excellent piece of study for investors who are looking towards the market. Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease, and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial. GlobalData epidemiologists used comprehensive, country-specific data from population based national health surveys such as NHANES in the US, the HSE in the UK, and the CHNS in urban China, in addition to data from peer-reviewed journal articles, to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of dyslipidemia, and other therapeutically significant patient populations including the total prevalent cases of increased LDLc and very high TG (=500mg/dL). Get Full Details On: http://www.researchbeam.com/epicast-report-dyslipidemia-epidemiology-forecast-to-2023-market

  3. Table of Contents 1 Table of Contents 5 1.1 List of Tables 7 1.2 List of Figures 9 2 Introduction 10 2.1 Catalyst 10 2.2 Related Reports 11 2.3 Upcoming Related Reports 12 3 Epidemiology 13 3.1 Disease Background 13 3.2 Risk Factors and Comorbidities 14 3.3 Global Trends 15 3.3.1 US 16 3.3.2 5EU 16 3.3.3 Asia 18 3.4 Forecast Methodology 19 3.4.1 Sources Used 27

  4. Table of Contents 4 Appendix 83 4.1 Bibliography 83 4.2 About the Authors 89 4.2.1 Epidemiologists 89 4.2.2 Reviewers 89 4.2.3 Acting Director of Epidemiology 90 4.2.4 Global Head of Healthcare 91 4.3 About GlobalData 92 4.4 About EpiCast 92 4.5 Disclaimer 93 Enquiry About report: http://www.researchbeam.com/epicast-report-dyslipidemia-epidemiology-forecast-to-2023-market/enquire-about-report

  5. Table of Contents Figure 1: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013-2023 61 Figure 2: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013 63 Figure 3: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, N, 2013 64 Figure 4: 8MM, Age-Standardized Total Prevalence of Dyslipidemia (%), Ages ?20 Years, by Sex, 2013 65 Figure 5: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ?20 Years, N, 2013-2023 67 Figure 6: 8MM, Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 68 Figure 7: 8MM, Age-Specific Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013 71 Figure 8: 8MM, Sex-Specific Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Ages ?20 Years, N, 2013 73 Figure 9: 8MM, Age-Standardized Total Prevalence of Increased LDLc (?115mg/dL to ?160mg/dL)* (%), Ages ?20 Years, by Sex, 2013 74 Figure 10: 8MM, Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 75

  6. Similar Market Studies Published Reports RESprotect GmbH - Product Pipeline Review - 2014 http://www.researchbeam.com/resprotect-gmbh-product-pipeline-review-2014-market Sylentis S.A. - Product Pipeline Review - 2014 http://www.researchbeam.com/sylentis-sa-product-pipeline-review-2014-market Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2014 http://www.researchbeam.com/actinium-pharmaceuticals-inc-product-pipeline-review-2014-market

  7. FOR MORE DETAILS Visit us at : http://www.researchbeam.com/epicast-report-dyslipidemia-epidemiology-forecast-to-2023-market Stay With Us: 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@researchbeam.com

More Related